Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study
Authors:
- Christine H. ChungCCChristine H. Chung
- Marcelo BonomiMBMarcelo Bonomi
- Conor E. SteuerCSConor E. Steuer
- Jiannong LiJLJiannong Li
- Priyanka BhatejaPBPriyanka Bhateja
- Matthew JohnsonMJMatthew Johnson
- Jude MasannatJMJude Masannat
- Feifei SongFSFeifei Song
- Juan C. Hernandez-PreraJHJuan C. Hernandez-Prera
- Bruce M. WenigBWBruce M. Wenig
- Helen MolinaHMHelen Molina
- Joaquim M. FarinhasJFJoaquim M. Farinhas
Open Access
Abstract
We hypothesized the combination of cetuximab and nivolumab would improve survival in recurrent and/or metastatic (R/M) HNSCC by providing synergy in cancer control and evaluated toxicities and efficacy of the combination. Effects of sequential administration of cetuximab and anti-Programmed Cell Death-1 checkpoint inhibitors (CPI) were also explored. Patients who failed at least one line of palliative treatment for incurable HNSCC were treated with cetuximab 500 mg/m2 IV on Day (D)-14 as a lead-in followed by cetuximab 500 mg/m2 IV and nivolumab 240 mg/m2 IV on D1 and D15 every 28-D cycle. Electronic health record-derived real-world data (RWD) were used to explore sequential treatment effects of CPI and cetuximab. A total of 45 evaluable patients were analyzed, and 31/45 (69%) patients had prior exposure to either CPI or cetuximab. The only grade 4 treatment-related adverse event was cetuximab infusion reaction in one patient. The 1-year progression-free survival (PFS) and overall survival (OS) rates were 19% and 44%, respectively. Although patients with no prior CPI (23/45, 51%) showed a trend for more favorable PFS relative to patients with prior CPI (22/45, 49%), the improvement in the 1-year OS did not reach the statistical threshold. For evaluation of sequential CPI and cetuximab treatment effects, we selected RWD-cetuximab cohort with 173 patients and RWD-CPI cohort with 658 patients from 6862 R/M HNSCC. Our result suggested patients treated with RWD-cetuximab after RWD-CPI had worse OS compared to no prior RWD-CPI (HR 1.81, 95% CI 1.02–3.16). Our data suggest the combination of cetuximab and nivolumab is well tolerated. Optimal sequencing of cetuximab and CPI may have an impact in prognosis and requires further evaluation.Keywords
Funding Information
- James and Esther King Biomedical Research Grant (7JK02)
- Lilly Oncology (Not applicable)
- National Cancer Institute, United States (P30-CA076292)
This publication has 31 references indexed in Scilit:
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trialThe Lancet, 2019
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionOral Oncology, 2018
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Distinct Risk Factor Profiles for Human Papillomavirus Type 16–Positive and Human Papillomavirus Type 16–Negative Head and Neck CancersJNCI: Journal of the National Cancer Institute, 2008
- Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck CancerNew England Journal of Medicine, 2007
- Case–Control Study of Human Papillomavirus and Oropharyngeal CancerNew England Journal of Medicine, 2007
- Tobacco and alcohol and the risk of head and neck cancerJournal of Molecular Medicine, 1992